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In the present review concerning stroke, we evaluate the roles of B vitamins, homocysteine and
antioxidant vitamins. Stroke is a leading cause of death in developed countries. However, current
therapeutic strategies for stroke have been largely unsuccessful. Several studies have reported
important benefits on reducing the risk of stroke and improving the post-stroke-associated
functional declines in patients who ate foods rich in micronutrients, including B vitamins and
antioxidant vitamins E and C. Folic acid, vitamin B6 and vitamin B12 are all cofactors in
homocysteine metabolism. Growing interest has been paid to hyperhomocysteinaemia as a risk
factor for CVD. Hyperhomocysteinaemia has been linked to inadequate intake of vitamins,
particularly to B-group vitamins and therefore may be amenable to nutritional intervention.
Hence, poor dietary intake of folate, vitamin B6 and vitamin B12 are associated with increased
risk of stroke. Elevated consumption of fruits and vegetables appears to protect against stroke.
Antioxidant nutrients have important roles in cell function and have been implicated in processes
associated with ageing, including vascular, inflammatory and neurological damage. Plasma
vitamin E and C concentrations may serve as a biological marker of lifestyle or other factors
associated with reduced stroke risk and may be useful in identifying those at high risk of stroke.
After reviewing the observational and intervention studies, there is an incomplete understanding
of mechanisms and some conflicting findings; therefore the available evidence is insufficient to
recommend the routine use of B vitamins, vitamin E and vitamin C for the prevention of stroke.
A better understanding of mechanisms, along with well-designed controlled clinical trials will
allow further progress in this area.
B vitamins: Homocysteine: Antioxidant vitamins E and C: Oxidative stress: Stroke
Introduction
Stroke is a leading cause of death in developed countries.
However, current therapeutic strategies for stroke have been
largely unsuccessful. It is estimated that stroke is
responsible for 9·5 % of all deaths and 5·1 million of the
16·7 million CVD deaths(1). Furthermore, nearly one-third
of stroke survivors have some degree of dementia after
stroke. Of patients who had ischaemic stroke, 32 % had
dementia based on comprehensive neurological and
psychological testing, clinical mental status interviews,
MRI scans and detailed histories collected(2 – 4). Importantly,
dementia is more common in stroke patients who are older,
smoke and have lower levels of education(2). In addition,
vascular dementia often coexists with Alzheimer’s disease,
and the presence of Alzheimer’s disease may predispose one
to the development of vascular dementia. In fact, the 5 %
prevalence in cognitive impairment that occurs in the
elderly over the age of 65 years increases sharply after
ischaemic stroke, up to 38 %. Cognitive impairment is
associated with death or disability at 4 years after a stroke(5).
But vascular dementia, which is the second most important
cause of cognitive impairment and dementia associated with
ageing in the USA, is the most preventable form affecting
the elderly.
The realisation that brain ischaemia elicits more robust
brain damage when nutritional status is poorer provides a
fertile ground for the discovery of novel therapeutic agents
and nutritional intervention for stroke. Deficiency of B
vitamins and antioxidant vitamins E and/or C appears to
increase cognitive impairment in stroke patients(6 – 8). Better
understanding of the role that specific nutrients play on
vasculature and brain’s cell response in stroke patients may
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be relevant to reduce the incidence of cognitive impairment
and dementia associated with stroke. Interestingly, B
vitamins play critical roles in cell function(9). For example,
folate in the 5-methyltetrahydrofolate form is a co-substrate
required by methionine synthase to convert homocysteine
(Hcy) to methionine; consequently, Hcy accumulates when
folate is low(10,11). High Hcy is strongly associated with
atherosclerotic vascular disease and stroke(12). Furthermore,
several surveys have shown positive correlation between
low folate levels and dementia(13). B12 is important in
maintaining the nervous system where it plays a vital role
in the metabolism of fatty acids essential to maintain
myelin(14). Vitamin B12 is also required for methionine
synthesis from Hcy(15). Prolonged B12 deficiency can lead to
nerve degeneration and irreversible neurological
damage(16). Vitamin B6 is needed for the synthesis
of neurotransmitters such as serotonin and dopamine.
A deficiency of vitamin B6 may also contribute to increase
levels of Hcy. Fig. 1 shows the biochemical pathways of
Hcy metabolism with the roles of folate, B6 and B12
(15).
Several reports have suggested a relevant effect of
dietary antioxidants, including vitamins E and C, on stroke
prevention(17 – 19). Ascorbic acid administration to a primate
model after focal cerebral ischaemia significantly reduced
the size of the infarct(20). Furthermore, data from the Third
National Health and Nutrition Examination Survey
(NHANES III) indicate a biological interaction between
ascorbic acid and alcohol and suggest that higher intake of
ascorbic acid may be associated with a decreased vascular
risk among drinkers(21). Among 87 245 US female
registered nurses, aged 34–59 years, higher antioxidant
vitamin consumption was associated with a reduced risk of
ischaemic stroke(19). In addition, high consumption of
cruciferous vegetables and citrus fruit juice reduced the risk
of stroke(22). From a 25-year follow-up study of middle-
aged men who participated in the Framingham Cardiovas-
cular Study(23) investigators re-examined 832 men, aged
45–65 years, who had been free of CVD when they began
the Framingham Study in 1969 and observed an inverse
association between fruit and vegetable intake and the
development of stroke.
A study of the intake of antioxidants and the risk of stroke
provides tantalising, albeit preliminary, evidence that
vitamin E might be of value in reducing the risk of
stroke(24). An inverse association was seen between death
from stroke and vitamin E intake from food, which reflected
a continued association from the lowest to the highest intake
categories, thus supporting a protective role for vitamin E
Fig. 1. Pathways for the metabolism of homocysteine. Normal trans-sulfuration requires cystathionine b synthase with vitamin B6 as cofactor.
Remethylation requires 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) and methionine synthase. The latter requires folate
as co-substrate and vitamin B12 (cobalamin) as cofactor. An alternative remethylation pathway also exists using the cobalamin-independent
betaine–homocysteine methyltransferase(15). DMG, dimethylglycine.
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or other antioxidant vitamins(24). Previous studies reported a
significant reduction in the incidence of ischaemic events in
patients taking vitamin E plus aspirin compared with
patients taking only aspirin(25 – 27). Vitamin C status may be
a determinant of cognitive function in elderly people
through its effect on atherogenesis. Low consumption
of vitamin C as well as low plasma levels were associated
with a greater risk of cognitive disorders in a 20-year
follow-up study(6).
As the number of older people grows rapidly worldwide,
along with the fact that elderly people are also living longer,
the risk of stroke and stroke-associated dementia – which is
one of the most common causes of cognitive impairment –
is increasingly becoming an important public health
problem. Since nutrition plays a role in the ageing process,
relatively simple and inexpensive treatments involving
dietary intervention and vitamin supplementation may
reduce the risk of stroke and ameliorate the neurological and
neurocognitive impairments associated with stroke. There-
fore, in the present review we will examine the potential role
that nutritional status – specifically B vitamins and
antioxidants – plays in reducing the deleterious effects
associated with stroke. Tables 1 and 2 show a summary of
some of the observational and intervention studies in the
literature regarding B vitamins, Hcy and stroke, and
antioxidant vitamins E and C and stroke, respectively.
Nutrition and stroke
The dietary guidelines of the American Heart Association
include specific recommendations tailored to an individual’s
risk of heart disease and stroke that are based on an analysis
of hundreds of studies(28). This recommended diet provides
a generous amount of micronutrients essential for good
health; however, a very small percentage of the population
follows it. In spite of these recommendations, several
studies have indicated that few of us eat well, and nutritional
deficiencies or low nutrient levels in tissues are very
common. For example, in a study of 402 elderly Europeans
living at home, the nutrient content of their diet was found to
be low: folate intake was low in 100 % of those studied, Zn
in 87 %, vitamin B6 in 83 % and vitamin D in 62 %
(29).
A cross-sectional study looking into the association of
dietary b-carotene, vitamin C and vitamin E with peripheral
arterial disease was performed in Rotterdam, the Nether-
lands, between 1990 and 1993 in 4367 subjects aged 55–94
years. Diet was assessed with a FFQ. In multivariate-
adjusted logistic regression analyses, vitamin C and E intake
was significantly inversely associated with peripheral
arterial disease(30).
Brussaard et al. (31) assessed the adequacy of folate intake
and status among adults in the Netherlands. They concluded
that the folate intake among adult men and women was
adequate in view of recommended daily intakes. However,
the folate intake among women did not meet the
recommendation for those who want to become pregnant.
According to criteria derived from Hcy metabolism
as related to CVD, folate status may not be adequate in
60–79 % of adult age–sex groups. However, the percentage
of adults with low folate status is going to vary widely
between countries dependent on folic acid fortification and
other dietary considerations.
Folate, riboflavin, vitamin B6 and vitamin B12 are
essential in Hcy metabolism, and elevated plasma Hcy
concentration is associated with an increased risk of CVD.
In a random sample of 2435 men and women, aged 20–65
years, who were examined between 1993 and 1996, B
vitamins were inversely related to the plasma Hcy
concentration; however, only folate intake remained
inversely associated with the plasma Hcy concentration
following multivariate-adjusted logistic regression ana-
lyses(32). Data consistently indicate that folic acid
supplementation in the form of vitamin tablets is the most
effective strategy to lower mild-to-moderately elevated
Hcy(33). However, in folic acid-fortified populations,
vitamin B12 status emerges as the most important
nutritionally modifiable determinant of Hcy levels(34,35).
Steps to either reduce the prevalence of vitamin B12
deficiency or to identify and treat individuals with vitamin
B12 deficiency could further reduce the prevalence of
hyperhomocysteinaemia(35).
To assess how changes in Hcy levels may influence post-
stroke response, Howard et al. (36) used a multicentre design
study to examine changes on Hcy during the 2 weeks after an
incident stroke. They collected blood samples from fifty-one
subjects at days 1, 3, 5, 7, and between 10 and 14 d after the
stroke. The estimated mean Hcy level at baseline was 11·3
(SEM 0·5) mmol/l, which increased consistently to 12·0 (SEM
0·05), 12·4 (SEM 0·5), 13·3 (SEM 0·5) and 13·7 (SEM 0·7)
mmol/l at days 3, 5, 7 and 10–14, respectively. The
magnitude of the changes in Hcy was not affected by age,
smoking status, alcohol use, history of hypertension or
diabetes, or Rankin scale score. This study would be
strengthened by an assessment of Hcy taken during the
convalescent period. With this additional assessment, the
authors would have been able to assess the proportion of
the change between the acute and convalescent period.
These observations suggest that the relevance and clinical
interpretation of Hcy after stroke require an adjustment in
time. Much of the evidence of the association of Hcy and
stroke risk is based on a comparison of Hcy levels after
stroke with Hcy levels of controls. The results by Howard
et al. (36) suggested that Hcy levels would be increased in
blood collected later after the stroke. Therefore, the
interpretation that a high Hcy level is a risk factor for stroke
may be misleading; rather, it could be that the elevated Hcy
is a consequence rather than a cause of the stroke.
Mezzano et al. (37) investigated the relative contributions
of inflammation and high Hcy to abnormal oxidative stress,
endothelial activation/dysfunction and haemostatic acti-
vation in patients with chronic renal failure, and concluded
that inflammation, endothelial cell dysfunction and
haemostatic activation emerge as a major cardiovascular
risk in chronic renal failure.
Observational studies support the importance of modify-
ing lifestyle-related risk factors such as diet, physical
activity and alcohol use in stroke prevention. Moderately
elevated Hcy levels may be associated with stroke and are
associated with deficiency of dietary intake of folate,
vitamin B6 and vitamin B12. Consumption of a diet rich in
fruits, vegetables, folate, K, Ca, Mg, dietary fibre, fish and
Vitamins, homocysteine and stroke 51
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Table 1. B vitamins, homocysteine (Hcy) and stroke
Study Study focus Subjects Results
Observational studies
Verhoef et al. (1994)(93) Levels of Hcy and risk of ischaemic stroke 14 916 male physicians aged
40–84 years
The data were compatible with a small but NS
association between elevated plasma Hcy
and risk of ischaemic stroke
Perry et al. (1995)(92) Hcy and risk of stroke in middle-aged
British men
107 stroke patients, 118 controls Hcy was significantly higher among stroke
patients than controls
Giles et al. (1998)(91) Hcy and the likelihood of non-fatal stroke 4534 US adults aged $ 35 years Hcy concentration was independently associated
with an increased likelihood of non-fatal stroke.
This association was present in both black
and white adults
Robinson et al. (1998)(60) Hcy, B vitamins and vascular diseases 750 patients with vascular disease,
800 control subjects
High Hcy is associated with an elevated risk
of vascular disease independent of all
traditional risk factors. Low folate and
vitamin B6 confer an increased risk of
atherosclerosis
Beamer et al. (1999)(67) Vitamin use in patients with ischaemic
stroke
231 stroke patients Use of vitamin supplements may be
associated with lower levels of Hcy in
elderly individuals whether or not stroke
or stroke-related risk factors are present
Bots et al. (1999)(95) Hcy, myocardial infarction and stroke in the
elderly: the Rotterdam Study
104 myocardial infarct patients,
120 stroke patients, 533 control subjects
The risk of stroke and myocardial infarction
increased with total Hcy
Clarke & Armitage (2000)(74) Vitamin supplements and CVD risk A meta-analysis of twelve randomised trials Dietary folate reduced Hcy levels by 25 %.
Vitamin B12 produced an additional reduction
in blood Hcy of 7 %, whereas vitamin B6
did not have any significant effect
Fallon et al. (2001)(94) Risk of ischaemic stroke and Hcy:
the Caerphilly study
2254 men aged 50–64 years No significant relationship between Hcy and
ischaemic stroke was observed in this
cohort. However, its aetiological importance
may be greater for premature ischaemic
strokes (,65 years)
Yoo & Lee (2001)(165) Elevated Hcy in elderly patients
with stroke
Fifty stroke patients, thirty-five controls Those elderly with elevated asymmetric
dimethylarginine concentrations are at
increased risk for ischaemic stroke; this
may account for increased risk of stroke
in patients with hyperhomocysteinaemia
Bazzano et al. (2002)(63) Dietary intake of folate and risk of
stroke and CVD
9764 men and women aged
25–74 years
Increasing dietary intake of folate from food
sources may be an important approach to
the prevention of CVD in the US population
Howard et al. (2002)(36) Hcy in the acute phase after stroke Seventy-six stroke patients aged
40–85 years
Hcy levels at baseline of 11·3 (SEM 0·5) mmol/l
increased consistently to 12·0 (SEM 0·05),
12·4 (SEM 0·5), 13·3 (SEM 0·5) and 13·7
(SEM 0·7) mmol/l at days 3, 5, 7 and 10–14,
respectively, after stroke. These data suggest
that the clinical interpretation of Hcy after
stroke and the eligibility for clinical trials
assessing treatment for elevated Hcy levels
require an adjustment in time since stroke
He et al. (2004)(73) Folate, vitamin B6 and B12 intakes
and risk of stroke
43 732 men free of CVD and diabetes
at baseline aged 40–75 years
Intake of vitamin B12, but not B6, was inversely
associated with risk of ischaemic stroke.
Increased folate intake was associated
with decreased risk of ischaemic stroke in men
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Iso (2005)(166) Elevated Hcy and risk of total stroke
and its subtypes
11 846 Japanese subjects High serum Hcy level (.11·0mmol/l) was
associated with a three-fold higher risk of
total stroke. The excess risk was confined to
ischaemic stroke, more specifically lacunar
infarction
Intervention studies
Spence et al. (2001)(69) Vitamins to prevent stroke 3688 stroke patients,
aged $ 35 years
The VISP study is a double-masked, randomised,
multicentre clinical trial designed to determine
if, in addition to best medical/surgical
management, high-dose folic acid, vitamin B6
and vitamin B12 supplements will reduce
recurrent stroke compared with lower doses
of these vitamins
VITATOPS Trial Study
Group (2002)(68)
Vitamins to prevent stroke 8000 stroke patients, any age The VITATOPS study follow-up of 8000 patients
between 2000 and 2009 provided a reliable
estimate of the safety and effectiveness of
dietary supplementation with folic acid,
vitamin B12 and vitamin B6 in reducing
recurrent serious vascular events and
transient ischaemic attacks stroke
Lonn et al. (2006)(65) Hcy and folic acid and B vitamins
in vascular disease
5522 patients with a history of
vascular disease aged $ 55 years
Supplements combining folic acid (2·5 mg)
and vitamins B6 (50 mg) and B12 (1 mg)
did not reduce the risk of major cardiovascular
events in patients with vascular disease
Albert et al. (2008)(64) Daily intake of folic acid and B vitamins
and risk of
cardiovascular events and total
mortality
5442 women aged $ 42 years After 7·3 years of treatment and follow-up, a
combination pill of folic acid (2·5 mg), vitamin B6
(50 mg) and vitamin B12 (1 mg) did not reduce
a combined end point of total cardiovascular
events among high-risk women, despite
significant Hcy lowering
Editorials and reviews
Kuller & Evans (1998)(90) Hcy, vitamins and CVD Editorial Possible associations between Hcy, B vitamins
and vascular disease
Perry (1999)(77,78) Hcy and risk of stroke Review High Hcy in apparently well-nourished populations
and the tendency of high Hcy with ageing,
and the effects of Hcy on stroke. Reduction
of Hcy will have profound implications for
public health
Goldstein (2000)(76) Hcy and risk of stroke Review Association between moderately elevated
levels of Hcy and stroke. Patients with chronic
inflammation, as well as those with chronic or
acute infection, are at elevated stroke risk
Robinson (2000)(15) Hcy, B vitamins and risk of CVD Editorial Routine measurement of Hcy still remains
speculative until the results of some of the
intervention trials became known
Rosenberg (2001)(58) B vitamins and cognitive function Review Importance of B vitamins (B6 and B12) and folate
in neurocognitive and other neurological
functions
Hankey (2002)(79) Hcy and risk of stroke Editorial Plasma Hcy and routine treatment of high
Hcy with vitamins to prevent symptomatic
cerebrovascular disease remains insufficient
VISP, Vitamin Intervention for Stroke Prevention; VITATOPS, Vitamins to Prevent Stroke.
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Table 2. Antioxidant vitamins E and C and stroke
Study Study focus Subjects Results
Observational studies
Arria et al. (1990)(122) Vitamin E deficiency Forty-two female patients with chronic
cholestatic liver disease
Vitamin E deficiency may underlie psychomotor
and neurological disturbance in adult patients
with chronic cholestatic liver disease
Gale et al. (1995)(6) Vitamin C and risk of death from
stroke
730 men and women who had no
history or symptoms of
stroke, aged $ 65 years
Low vitamin C status was associated with
highest mortality from stroke. The relationship
between vitamin C intake and stroke was
independent of social class and other
dietary variables
Gillman et al. (1995)(23) Intake of fruits and vegetables
and stroke
832 men aged 45–65 years Fruits and vegetables protect against
development of stroke in men
Keli et al. (1996)(167) Antioxidants and stroke: the
Zutphen study
552 men aged 50–69 years Intake of vitamins C and E was not associated
with stroke risk
Daviglus et al. (1997)(168) Vitamin C and stroke. The
CWE Study
1843 middle-aged men A modest decrease in risk of stroke with
higher intake of b-carotene and vitamin C
intake was observed. These data do not
provide definitive evidence that a high intake
of antioxidant vitamins decreases the
risk of stroke
Schmidt et al. (1998)(127) Antioxidants and cognitive function 1769 subjects with no history or
signs of neuropsychiatric
disease, aged 50–75 years
Dietary antioxidants appear to protect against
cognitive impairment in older individuals
Simon et al. (1998)(140) Vitamin C, CVD and stroke. Second
NHNE Survey
6624 US men and women Serum ascorbic acid levels were independently
associated with prevalence of CHD and
stroke; a 5 mg/l increase in serum ascorbic
acid level was associated with an 11 %
reduction in CHD and stroke prevalence
Ascherio et al. (1999)(17) Vitamins E and C and risk of stroke 437 38 men who did not have
CVD or diabetes, aged 40–75 years
Vitamin E and C supplements and specific
carotenoids did not seem to substantially
reduce the risk of stroke in this cohort
Foy et al. (1999)(138) Antioxidants and AD, vascular
disease and PD
Seventy-nine patients with AD,
thirty-seven patients with
vascular disease, eighteen
patients with PD
A reduction in plasma antioxidants in patients
with dementia. Increased free radical
activity in vascular disease and PD may
be associated with concomitant AD pathology
Joshipura et al. (1999)(147) Fruit and vegetable intake
and stroke
114 279 men and women
aged 34–75 years
Consumption of fruit and vegetables,
particularly cruciferous and green leafy
vegetables and citrus fruit and juice,
provide a protective effect against risk of
ischaemic stroke
Perkins et al. (1999)(126) Vitamins E, C and A, carotenoids,
Se and poor memory performance
4809 non-Hispanic white,
non-Hispanic black and
Mexican-American elderly
Decreasing serum levels of vitamin E were
associated with poor memory after
adjustment for age, education, income,
vascular risk factors, and other trace
elements and minerals
Simon & Hudes (1999)(21) Vitamin C and CVD. Third NHNE Survey 7658 men and women A higher intake of vitamin C may be associated
with a decreased risk of angina among drinkers
Cherubini et al. (2000)(158) Vitamins C and E, SOD and glutathione
peroxidase in stroke patients
Thirty-eight control subjects,
thirty-eight subjects
with acute ischaemic stroke
Reduction of antioxidants immediately after ischaemic
stroke, possibly as a consequence of increased
oxidative stress. A specific antioxidant profile is
associated with a poor early outcome
Yochum et al. (2000)(24) Antioxidants and risk of death
from stroke
34 492 postmenopausal women An inverse association between death from stroke
and intakes of vitamin E from food was observed
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Hirvonen et al. (2000)(169) Vitamins C and E and risk of stroke 26 593 male smokers,
aged 50–69 years
Vitamin E was not associated with any subtype
of stroke. Dietary vitamin C was inversely
associated with risk for intracerebral haemorrhage,
whereas no association was found between intake of
vitamin C and risks for cerebral infarction and
subarachnoid haemorrhage
Yokoyama et al. (2000)(170) Vitamin C and stroke. The
Shibata Study
2121 Japanese men and women
aged $ 40 years
Serum vitamin C concentration was inversely associated
with incidence of stroke, both cerebral infarction
and haemorrhagic stroke
Polidori et al. (2001)(171) Vitamins C and E, uric acid and
ubiquinol-10
Forty control subjects, thirteen patients
with intracranial haemorrhage, fifteen
patients with head trauma
Intracranial and head trauma patients had
significantly lower plasma levels of vitamin C
compared with healthy subjects. Ascorbic acid was
significantly inversely correlated with the severity
of the neurological impairment and with the major
diameter of the lesion
Kurl et al. (2002)(145) Vitamin C and risk of stroke 2419 men with no history of stroke at
baseline examination aged
42–60 years
Low plasma vitamin C was associated with an increased
risk of stroke, especially among hypertensive and
overweight men
Voko´ et al. (2003)(172) Intake of antioxidants from
food and risk of stroke
5197 participants High dietary intake of antioxidants, in particular vitamin C
and – in smokers – vitamin E, reduced the risk
of stroke
Myint et al. (2008)(146) Plasma vitamin C concentrations
and risk of incident stroke
20 649 men and women without
prevalent stroke at baseline
aged 40–79 years
Plasma vitamin C concentrations may serve as a
biological marker of lifestyle or other factors
associated with reduced stroke risk and may be useful
in identifying those at high risk of stroke
Intervention studies
Shorer et al. (1996)(123) Vitamin E deficiency Four siblings Vitamin E administration in pharmacological doses
improved the neurological condition in two patients
and also corrected some of the patients’ erythrocyte
cell abnormalities
Sano et al. (1997)(142) Vitamin E and AD 341 AD patients Vitamin E slowed the progression of AD
Benson et al. (1999)(173) Vitamin E and stroke.
The NOMAS Study
342 stroke patients, 501 control
subjects
Vitamin E supplementation showed a protective
effect against ischaemic stroke
Leppa¨la¨ et al. (2000)(18,129) Vitamin E supplementation
and stroke
29 133 male smokers aged
50–69 years
Vitamin E supplementation appears to have a
significant effect in preventing ischaemic stroke
in high-risk hypertensive patients
Lonn (2005)(135) Vitamin E and cardiovascular
events
3994 patients with vascular disease
or diabetes mellitus, aged
$ 55 years
In patients with vascular disease or diabetes mellitus,
long-term vitamin E supplementation does not
prevent cancer or major cardiovascular events and
may increase the risk for heart failure
Cook et al. (2007)(148) Vitamins C and E and b-carotene
and secondary prevention of
cardiovascular events
8171 female health professionals
at increased risk of CVD
aged $ 40 years
There were no overall effects of ascorbic acid,
vitamin E or b-carotene on cardiovascular events
among women at high risk for CVD
Reviews
Padh (1991)(143) Vitamin C: its biochemical functions Review Ascorbate and other antioxidant nutrients are
presumed to play a pivotal role in minimising the
damage from oxidative products
Ness et al. (1996)(141) Vitamin C and CVD Review Vitamin C’s protective effect against stroke is well
documented whereas the evidence that vitamin C
is protective against CHD is less consistent
Launer & Kalmijn
(1998)(125)
Antioxidants and cognitive function Review Effect of antioxidants on cognitive impairment or
dementia needs further investigation
V
itam
in
s,
h
o
m
o
cy
stein
e
an
d
stro
k
e
5
5
Nutrition Research Reviews
milk may protect against stroke(22,38 – 42). There is also
evidence that a low serum albumin may be causally linked
to stroke risk and outcome and that a significant number of
stroke patients are undernourished on admission and their
nutritional status deteriorates further whilst in hospi-
tal(40,43,44) (about a fifth of patients with acute stroke are
malnourished on admission to hospital). Moreover, patients’
nutritional status often deteriorates thereafter because of
increased metabolic demands, which cannot be met due to
feeding difficulties. Poor nutritional intake may result from
a reduced consciousness level, unsafe swallowing, arm or
facial weakness, poor mobility, or ill-fitting dentures(45 – 48).
Large randomised trials are now in progress to identify the
optimum feeding policies for stroke patients. Experimental
research has consistently suggested that diet-related factors
play an important role in cognitive functions in ageing. In
humans, a number of epidemiological case–control and
prospective studies analysed the association between
nutrition, particularly fatty acids and antioxidant molecules
(vitamins A, E and C, b-carotene and polyphenols) and
cognition and risk of stroke(49). In fact, intensive research
has indicated that subclinical deficiencies of essential
nutrients such as antioxidants (vitamins C and E),
b-carotene, vitamin B12, vitamin B6 and folate in
combination with nutrition-related disorders, such as
hypercholesterolaemia, hypertriacylglycerolaemia, hyper-
tension and diabetes, are important risk factors associated
with cognitive impairment(8). Current scientific evidence
also suggests a protective role for fruits and vegetables in
the prevention of CHD, and evidence is accumulating
towards a protective role in stroke(22,42,50 – 52). On the other
hand, intake of monounsaturated fat has been associated
with reduced risk of ischaemic stroke in men(53). Another
study has found that higher intake of wholegrain foods was
associated with lower risk of ischaemic stroke among
women, independent of known CVD risk factors. These
prospective data support the notion that higher intake of
whole grains may reduce the risk of ischaemic stroke(19).
Higher consumption of fish and n-3 PUFA is associated with
a reduced risk of thrombotic infarction, primarily among
women who do not take aspirin regularly(54). Other authors
also have reported that fish consumption is associated with a
reduced risk from all-cause, IHD and stroke mortality at the
population level(55).
Thus, B vitamins and antioxidant nutrients have important
roles in cell function and have been implicated in processes
associated with ageing including vascular, inflammatory and
neurological damage. A large body of evidence indicates that
micronutrient status is an important determinant of vascular
dysfunction and that deficiencies contribute to vasculature
changes in the brain, risk of stroke, and alterations in brain
function and cognitive impairment in the elderly. However,
how these factors are causally interrelated remains poorly
understood. Previous studies have focused on atherosclerosis
and loss of innervation as the main changes involved in
ageing-related vascular impairments.
B vitamins: folate, vitamin B12 and vitamin B6
The major manifestation of folate deficiency is megalo-
blastic anaemia. Gastrointestinal disturbances may also
T
a
b
le
2
.
C
o
n
ti
n
u
e
d
S
tu
d
y
S
tu
d
y
fo
c
u
s
S
u
b
je
c
ts
R
e
s
u
lt
s
B
e
h
l
(1
9
9
9
)(
1
2
4
)
V
ita
m
in
E
in
n
e
u
ro
p
ro
te
c
ti
o
n
R
e
v
ie
w
A
s
lo
n
g
a
s
s
p
e
c
ifi
c
in
te
rv
e
n
ti
o
n
s
a
re
n
o
t
a
v
a
ila
b
le
,
th
e
o
p
ti
m
is
ti
c
d
a
ta
c
o
n
c
e
rn
in
g
th
e
n
e
u
ro
p
ro
te
c
ti
v
e
a
c
ti
v
it
y
o
f
a
n
ti
o
x
id
a
n
ts
in
v
itr
o
a
n
d
in
v
iv
o
u
n
d
e
rl
in
e
a
n
im
p
o
rt
a
n
t
ro
le
fo
r
a
n
ti
o
x
id
a
ti
v
e
-a
c
tin
g
c
o
m
p
o
u
n
d
s
fo
r
th
e
p
re
v
e
n
ti
o
n
a
n
d
th
e
ra
p
y
o
f
o
x
id
a
ti
v
e
s
tr
e
s
s
-r
e
la
te
d
c
o
n
d
it
io
n
s
in
c
lu
d
in
g
A
D
V
a
ta
s
se
ry
e
t
a
l.
(1
9
9
9
)(
1
7
4
)
V
ita
m
in
E
a
n
d
c
e
n
tr
a
l
n
e
rv
o
u
s
s
y
s
te
m
d
is
o
rd
e
rs
R
e
v
ie
w
U
s
e
o
f
v
it
a
m
in
E
in
p
h
a
rm
a
c
o
lo
g
ic
a
l
d
o
s
e
s
in
th
e
tr
e
a
tm
e
n
t
o
f
d
is
o
rd
e
rs
s
u
c
h
a
s
P
D
,
A
D
a
n
d
ta
rd
iv
e
d
y
s
k
in
e
s
ia
S
u
te
r
(2
0
0
0
)(
1
7
5
)
V
ita
m
in
E
,
v
it
a
m
in
C
a
n
d
s
tr
o
k
e
R
e
v
ie
w
C
o
n
s
u
m
p
tio
n
o
f
fr
u
it
s
,
v
e
g
e
ta
b
le
s
a
n
d
a
n
ti
o
x
id
a
n
t
n
u
tr
ie
n
ts
m
a
y
re
p
re
s
e
n
t
a
n
e
ffi
c
ie
n
t
s
tr
a
te
g
y
to
re
d
u
c
e
s
tr
o
k
e
ri
s
k
F
e
ld
m
a
n
(2
0
0
1
)(
2
2
)
F
ru
its
a
n
d
v
e
g
e
ta
b
le
s
a
n
d
ri
s
k
o
f
s
tr
o
k
e
R
e
v
ie
w
T
w
o
la
rg
e
-s
c
a
le
p
ro
s
p
e
c
tiv
e
o
b
s
e
rv
a
tio
n
a
l
s
tu
d
ie
s
lin
k
e
d
th
e
c
o
n
s
u
m
p
ti
o
n
o
f
fr
u
it
s
a
n
d
v
e
g
e
ta
b
le
s
w
it
h
th
e
ri
s
k
o
f
is
c
h
a
e
m
ic
s
tr
o
k
e
:
c
ru
c
if
e
ro
u
s
v
e
g
e
ta
b
le
s
a
n
d
c
itr
u
s
fr
u
it
ju
ic
e
p
ro
v
id
e
d
th
e
g
re
a
te
st
p
ro
te
c
ti
o
n
R
e
n
a
u
d
(2
0
0
1
)(
4
2
)
D
ie
t
a
n
d
s
tr
o
k
e
R
e
v
ie
w
F
ru
it,
v
e
g
e
ta
b
le
s
a
n
d
fo
la
te
m
a
y
h
a
v
e
im
p
o
rt
a
n
t
p
ro
te
c
tiv
e
e
ff
e
c
t
o
n
s
tr
o
k
e
C
W
E
S
tu
d
y
,
T
h
e
C
h
ic
a
g
o
W
e
s
te
rn
E
le
c
tr
ic
S
tu
d
y
;
N
H
N
E
S
u
rv
e
y
,
N
a
ti
o
n
a
l
H
e
a
lt
h
N
u
tr
it
io
n
E
x
a
m
in
a
ti
o
n
S
u
rv
e
y
;
A
D
,
A
lz
h
e
im
e
r’
s
d
is
e
a
s
e
;
P
D
,
P
a
rk
in
s
o
n
’s
d
is
e
a
s
e
;
S
O
D
,
s
u
p
e
ro
x
id
e
d
is
m
u
ta
s
e
;
N
O
M
A
S
,
T
h
e
N
o
rt
h
e
rn
M
a
n
h
a
tt
a
n
S
tr
o
k
e
S
tu
d
y
.
C. Sa´nchez-Moreno et al.56
N
u
tr
it
io
n
R
es
ea
rc
h
R
ev
ie
w
s
accompany folate deficiency. Numerous animal studies have
also shown that folate deficiency during pregnancy can
impair proper development of fetal central nervous system
structures. Folate deficiency in pregnant women is
associated with an increased incidence of spina bifida and
other neural defects(56). Vitamin B12 deficiency in adults is
usually not the result of reduced dietary intake but rather
reflects reduced intestinal absorption of the vitamin. A
number of disease conditions can alter production of the
intrinsic factor that is essential for absorption of vitamin B12
from the intestine. Atrophic gastritis is an important cause of
vitamin B12 malabsorption. This condition primarily affects
the ability to extract vitamin B12 from foods. Deficiency of
vitamin B12 impairs the ability of the bone marrow to
produce erythrocytes and thus leads to anaemia, similar to
what is observed with folate deficiency. Vitamin B12
deficiency can also result in irreversible damage to the
nervous system causing swelling, demyelination and death
of neurons.
Evidence of the importance of the B vitamins folic acid,
vitamin B12 and vitamin B6 for the wellbeing and normal
function of the brain derives from data showing neurological
and psychological dysfunction in vitamin-deficiency states
and in cases of congenital defects of one-carbon
metabolism. A review by Selhub et al. (57) indicated that
the status of these vitamins is frequently inadequate in the
elderly and recent studies have shown associations between
loss of cognitive function or Alzheimer’s disease and
inadequate B vitamin status. The authors suggest that low B
vitamin intake may affect methylation reactions, which are
crucial for normal brain function. Poor B vitamin status can
also result in high Hcy, a risk factor for occlusive vascular
disease, stroke and thrombosis and thus may contribute to
brain ischaemia. Evidence of the importance of B vitamins
(B12, B6 and folate) in neurocognitive and other
neurological functions is derived from reported cases of
severe vitamin deficiencies, particularly pernicious anae-
mia, or homozygous defects in genes that encode for
enzymes of one-carbon metabolism(58); however, the data
from a recent systematic review of randomised trials do not
yet provide adequate evidence of an effect of vitamin B6 or
B12 or folic acid supplementation, alone or in combination,
on cognitive function testing in individuals with either
normal or impaired cognitive function(59). Low levels of
folate and vitamin B6 have been regarded to confer an
increased risk of atherosclerosis(60). High plasma Hcy
concentration is a risk factor for atherosclerosis, and
circulating concentrations of Hcy are related to vitamin B12
status, as well as folate and vitamin B6. If elevated Hcy
promotes cognitive dysfunction, then lowering Hcy by
means of B vitamin supplementation may protect cognitive
function by arresting or slowing the disease process(61).
Although elevated plasma Hcy concentrations have been
implicated in the risk of cognitive impairment and dementia,
it is unclear whether low vitamin B12 or folate status is
responsible for cognitive decline(62).
Various studies have suggested that a generous intake of
folate and B vitamins may be beneficial in stroke prevention
by reducing the level of plasma Hcy(60). The association
between dietary intake of folate and the subsequent risk of
stroke and CVD is well documented. Participants in the
National Health and Nutrition Examination Survey I
(NHANES I) included 9764 US men and women aged
25–74 years who were free of CVD at baseline. The results
showed that the relative risk of incidence of stroke events
was lower among subjects with dietary folate intake in the
highest quartile (405·0mg/d) compared with those in the
lowest quartile (99·0mg/d), after adjustment for established
cardiovascular risk factors and dietary factors(63). A recent
study evaluated whether a combination of folic acid, vitamin
B6 and vitamin B12 lowers the risk of CVD among high-risk
women with and without CVD. A total of 5442 women who
were US health professionals aged 42 years or older, with
either a history of CVD or three or more coronary risk
factors, were enrolled in a randomised, double-blind,
placebo-controlled trial to receive a combination pill
containing 2·5 mg folic acid, 50 mg vitamin B6 and 1 mg
vitamin B12. They were treated for 7·3 years from April
1998 until July 2005. After 7·3 years of treatment and
follow-up, the combination of B vitamins tested did not
reduce a combined end point of total cardiovascular events
among high-risk women, despite significant Hcy low-
ering(64). In addition, the results of the Heart Outcomes
Prevention Evaluation (HOPE-2) study, showed that
combined daily administration of 2·5 mg folic acid, 50 mg
vitamin B6 and 1 mg vitamin B12 for 5 years had no
beneficial effects on major vascular events in a high-risk
vascular disease population(65), although fewer patients
assigned to active treatment than to placebo had a stroke
(relative risk 0·75; 95 % CI 0·59, 0·97). As well, Bønaa
et al. (66) evaluated the efficacy of Hcy-lowering treatment
with B vitamins for secondary prevention in patients who
had had an acute myocardial infarction. The trial included
3749 men and women who had had an acute myocardial
infarction within 7 d before randomisation. Patients were
randomly assigned, in a 2 £ 2 factorial design, to receive
one of the following four daily treatments: 0·8 mg folic
acid, 0·4 mg vitamin B12 and 40 mg vitamin B6; 0·8 mg folic
acid and 0·4 mg vitamin B12; 40 mg vitamin B6; or placebo.
The primary end point during a median follow-up of 40
months was a composite of recurrent myocardial infarction,
stroke and sudden death attributed to coronary artery
disease. The authors conclude that treatment with B
vitamins did not lower the risk of recurrent CVD after
acute myocardial infarction.
The folic acid fortification programme in the USA has
decreased the prevalence of low levels of folate and
hyperhomocysteinaemia to 1 % or lower(35). Folate is
distributed widely in green leafy vegetables, citrus fruits and
animal products. The biologically active form of folic acid is
tetrahydrofolic acid, which plays a key role in the transfer of
one-carbon units, such as methyl, methylene and formyl
groups, to the essential substrates involved in the synthesis
of DNA, RNA and proteins. More specifically, tetrahy-
drofolic acid is involved in the enzymic reactions necessary
for the synthesis of purine, thymidine and amino acids.
Manifestations of folate deficiency, thereafter, not surpris-
ingly, would result in impairment of cell division,
accumulation of possibly toxic metabolites such as Hcy,
and impairment of methylation reactions involved in the
regulation of gene expression. Mechanistically speaking,
current theory proposes that folate is essential for the
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synthesis of S-adenosylmethionine, which is involved in
numerous methylation reactions. This methylation process
is central to the biochemical basis of proper neuropsychia-
tric functioning.
A large body of evidence suggests that intake of folate
and B vitamins may be beneficial in stroke prevention by
reducing levels of plasma Hcy; however, limited infor-
mation is available regarding dietary intake of vitamins or
use of vitamin supplements by stroke patients. Beamer
et al. (67) collected information regarding the use of vitamin
supplements from 231 patients with acute ischaemic stroke.
These authors also recorded vitamin intake from ninety-four
subjects with similar clinical risk factors for stroke,
including hypertension, diabetes, myocardial ischaemia,
and fifty-nine healthy community volunteers who denied the
presence of stroke risk factors and who were matched in age
with the two vascular groups. Fewer subjects who had stroke
were taking vitamins, compared with healthy elderly
community volunteers. In addition, Hcy levels available
from forty-nine stroke patients, thirty-one patients with
stroke risk factors and seven control subjects were
significantly lower in subjects taking vitamins. The pattern
of lower Hcy values with vitamin use was consistent across
groups, including stroke patients (13·9 (SD 6·7) v. 14·6
(SD 4·1) mmol/l), at-risk elderly subjects (13·5 (SD 4·3)
v. 15·0 (SD 6·9) mmol/l) and healthy elderly subjects (7·1
(SD 0·1) v. 10·5 (SD 2·3) mmol/l). It was concluded that Hcy
levels are influenced by a complex interaction of sex, dietary
levels of protein intake, dietary and/or supplemental vitamin
use and cardiovascular risk factors. These results suggest
that the use of vitamin supplements may be associated with
lower levels of Hcy in elderly individuals whether or not
stroke or stroke-related risk factors are present. Also, these
data suggest that less frequent use of vitamin supplemen-
tation in the elderly may be associated with an increased risk
for stroke(67). Different epidemiological studies suggest that
raised plasma concentrations of total Hcy may be a
common, causal and treatable risk factor for atherothrom-
boembolic ischaemic stroke. Therefore, a study aimed to
assess the effect of Vitamins to Prevent Stroke (VITATOPS)
– an international, multi-centre, randomised, double-blind,
placebo-controlled clinical trial – using a multivitamin
therapy (folic acid 2 mg, vitamin B6 25 mg, vitamin B12
500mg) is currently going on. It is planned that 8000
patients will be randomised and followed up for a mean
period of 2·5 years (range 1–8 years) by the end of 2009(68).
This study is expected to generate relevant data on the
potential role of these nutrients on stroke and other
atherothromboembolic vascular events in patients with
recent stroke or transient ischaemic attacks. Publication of
the results of the landmark Vitamin Intervention for Stroke
Prevention (VISP) Trial is the first evidence from a large
randomised controlled trial of the effect of lowering total
Hcy via folic acid-based multiple B vitamin supplemen-
tation on the incidence of ‘hard’ clinical events, such as
recurrent stroke, in patients with recent ischaemic
stroke(69,70). Hankey & Eikelboom(71) believe that the Hcy
hypothesis of atherothrombotic vascular disease in general,
and stroke in particular, remains viable. Two studies using
different methods have yielded consistent results in support
of the hypothesis(72,73).
Several studies are in progress to determine whether
treatment with folic acid in combination with vitamins B6
and B12 will reduce the risk of stroke in patients with
increased serum Hcy. A meta-analysis of twelve randomised
trials of vitamin supplements to lower Hcy levels was
carried out to determine the optimal dose of folic acid
required to lower Hcy levels and to assess whether
vitamin B12 or vitamin B6 had additive effects
(74). This
meta-analysis demonstrated that reductions in blood Hcy
levels were greater at higher pre-treatment blood Hcy levels
and at lower pre-treatment folate concentrations. After
standardisation for a pre-treatment Hcy concentration of
12mmol/l and folate concentration of 12 nmol/l (approxi-
mate average concentrations for Western populations),
dietary folate acid reduced Hcy levels by 25 (95 % CI 23,
28) %, with similar effects in a daily dosage ranging from
0·5 to 5 mg. Vitamin B12 (mean 0·5 mg) produced an
additional reduction in blood Hcy of 7 %, whereas vitamin
B6 (mean 16·5 mg) did not have any significant effect.
Hence, in typical populations, daily supplementation with
both 0·5 to 5 mg folic acid and about 0·5 mg vitamin B12
would be expected to reduce Hcy levels by one-quarter to
one-third (from about 12mmol/l to about 8 to 9mmol/l).
Large-scale randomised trials of such regimens are now
required to determine whether lowering Hcy levels by folic
acid and vitamin B12, with or without added vitamin B6,
reduces the risk of vascular disease.
In this sense, it has also to be considered on one hand that
high doses of folic acid may mask the megaloblastic
anaemia due to vitamin B12 deficiency seen in elderly
individuals as a result of atrophic gastritis. On the other
hand, we have to be aware that vitamin B6 status is primarily
a determinant of postprandial Hcy levels, but not fasting
levels. Thus, in studies of B vitamin supplements and Hcy, it
often appears that vitamin B6 has little effect on Hcy levels
because these studies typically only look at fasting Hcy
levels.
In addition, it is interesting to consider the issue of folic
acid fortification. In the USA and Canada, folic acid
fortification of enriched grain products was fully
implemented by 1998. Yang et al. (75) evaluated trends
in stroke-related mortality before and after folic acid
fortification in the USA and Canada and, as a comparison,
during the same period in England and Wales, where
fortification is not required. They observed a trend
consistent with the hypothesis that folic acid fortification
is contributing to a reduction in stroke deaths.
Patients with chronic inflammation as well as those with
chronic or acute infection are at elevated stroke risk(76). Due
to the high prevalence of high Hcy among apparently well-
nourished populations and the tendency for Hcy concen-
trations to increase with age, and the effects of Hcy on
stroke risk, lowering the levels of Hcy may have profound
implications for public health(77,78). However, according to
Robinson(15), the benefit of routine measurement of Hcy
concentrations remains speculative until the results of some
of the intervention trials become known. In the same sense,
Hankey(79) concluded that there is not sufficient evidence to
recommend routine screening of plasma Hcy and routine
treatment of high Hcy concentrations with vitamins to
prevent symptomatic cerebrovascular disease.
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Homocysteine
A high Hcy concentration is an independent risk factor for
coronary artery disease, stroke, peripheral vascular athero-
sclerosis, and for arterial and venous thromboembolism,
although the mechanisms for this effect remain poorly
understood. The association between cognitive function and
risk of death from stroke suggests that cerebrovascular
disease is an important cause of declining cognitive
function. Hcy is believed to cause atherogenesis and
thrombogenesis via endothelial damage, focal vascular
smooth muscle proliferation probably causing irregular
vascular contraction and coagulation abnormalities(80). The
significance of any association between CVD and stroke,
and circulating Hcy concentrations is attracting consider-
able attention(80 – 90). Morris et al.(89) evaluated the
association between serum Hcy concentration and self-
report heart attack or stroke in adult male and female
participants in the Third National Health and Nutrition
Examination Survey (NHANES III). The study reported
2·4 times more episodes of heart attack or stroke in men with
Hcy concentration of . 12mmol/l than among individuals
with lower values. According to Kuller & Evans(90), Hcy
and B vitamin levels may contribute to the development of
vascular disease through mechanisms independent of the
atherosclerosis process. In fact, whereas high Hcy levels are
directly related to the development of atherosclerosis, a
decrease in folate or vitamin B12 and vitamin B6 increases
the risk of vascular disease independently of atherosclerosis.
High Hcy levels could be associated with an enhancement of
inflammatory process and increased risk of thrombosis.
Giles et al.(91) found that in a representative sample of US
adults, Hcy concentration was independently associated
with an increased likelihood of non-fatal stroke, and this
association was present in both black and white adults. In a
different study, Perry et al.(92) measured serum Hcy levels in
107 cases and 118 control males, matched for age and
without a history of stroke at the time of screening; some of
them did develop stroke or myocardial infarction during
follow-up. Levels of Hcy were not very high but lower in
controls (11·3–12·6mmol/l) than among cases (12·7–
14·8mmol/l). Other studies have also indicated that small
differences in Hcy levels may significantly contribute to
increase the risk of ischaemic stroke(93 – 95).
A high concentration of Hcy appears to have significant
effect on platelets’ function and it may be relevant to blood–
brain barrier changes. The neurotoxicity of Hcy acting
through the overstimulation of N-methyl-D-aspartate
receptors could be one of the mechanisms that contribute
to neuronal damage in high Hcy(96). In addition to a possible
direct pathological effect of Hcy on the endothelium,
elevated Hcy levels lead to the development and progression
of vascular disease by affecting platelets’ function and
aggregation(97). Mutus et al. (98) showed that Hcy-induced
inhibition of NO production in platelets was lower in
platelets from diabetic patients than in platelets from control
subjects. Other studies have suggested that moderate to high
Hcy levels play a role in the development of a thrombogenic
state through oxidative stress-mediated insult(99).
High Hcy levels are also associated with atherosclerosis,
thromboembolism and vascular endothelial cell
injury(100,101). The effect of Hcy in developing thrombosis
may be associated with an inhibitory action on endothelial
cell thrombomodulin expression, which was independent of
platelet aggregation or heparin cofactor activity(102). In
severe high homocysteinaemia, circulating endothelial cells
have been detected(103,104), indicative of endothelial cell
death. Also, Hcy induces apoptosis in human umbilical vein
endothelial cells by activation of the unfolded protein
response(105). In the same way, Hcy-thiolactone induced
endothelial cell apoptosis in a concentration-dependent
manner with concentrations that ranged from 50 to
200mmol/l, independently of the caspase pathway(106).
Wang et al.(107), using a concentration that overlaps
clinically, observed levels of 10–50mmol Hcy per litre,
inhibited DNA synthesis in vascular endothelial cells and
arrested their growth at the G1 phase of the cell cycle.
Chambers et al. (108) detected endothelial dysfunction at
Hcy concentrations similar to those associated with
increased risk of myocardial infarction and stroke.
Interestingly, pre-treatment of cells with vitamin C
prevented the decrease in flow-mediated dilatation after
methionine. Thus, elevation of Hcy concentration appears to
be associated with an acute impairment of vascular
endothelial cell function that can be prevented by pre-
treatment with vitamin C in healthy subjects(108). Another
important finding is the molecular association between the
atherosclerotic process and high Hcy. Li et al.(109), using a
cDNA microarray, found an unexpected link between Hcy
and cholesterol dysregulation with increased levels of
3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA
and protein in endothelial cells, suggesting a possible role of
Hcy-induced changes in endothelial cells. Interestingly,
the use of statins improved endothelial NO production in
Hcy-treated endothelial cells. To study the mechanisms by
which Hcy may promote vascular modifications, Kokame
et al.(110) applied a non-radioactive differential display
analysis to evaluate changes in gene expression induced by
Hcy in human umbilical vein endothelial cell culture. They
identified six up-regulated genes and one down-regulated
gene, revealing that Hcy alters the expression of multiple
proteins, some of them associated with the endoplasmic
reticulum stress response(111). Outinen et al.(112) demon-
strated using human umbilical endothelial cells that Hcy
causes adverse effects on the endoplasmic reticulum,
altering the expression of several genes sensitive to
endoplasmic reticulum stress. They also showed that Hcy
altered various genes known to mediate cell growth and
differentiation. In addition, they observed that Hcy altered
the gene profile involved in the expression of cellular
proteins such as glutathione peroxidase and superoxide
dismutase, thus potentially enhancing the cytotoxic effects
of agents or conditions known to cause oxidative
damage(112). Another study using human endothelial cells
demonstrated that Hcy may act upon the vasculature through
activation of kinases such as Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK), and subsequent
expression of transcription factor ATF3 involved in
the regulation of synthesis of proteins critical for
endothelial cell function(113).
Pathophysiological levels of L-Hcy can alter endothelial
cell function. Poddar et al.(114) demonstrated that cultured
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human aortic endothelial cells exposed to as little as 10mM-
DL-Hcy up-regulated the expression of chemokines such as
monocyte chemoattractant protein-1 (MCP-1) and IL-8.
Maximal expression was achieved with 50mM-DL-Hcy
within 2–4 h of incubation. This suggests that Hcy may
contribute to the initiation and progression of vascular
disease by promoting leucocyte recruitment. Holven
et al.(115) suggested that Hcy exerts its atherogenic effects
in part by enhancing chemokine expression in cells involved
in atherogenesis and that folic acid supplementation may
down-regulate these inflammatory responses. On the other
hand, the recruitment of monocytes is an important event in
atherogenesis. MCP-1 is a potent chemokine that stimulates
monocyte migration into the intima of arterial walls. In the
same manner, Wang et al.(116) investigated the effect of Hcy
on MCP-1 expression in macrophages and the underlying
mechanism of this effect. They demonstrated that Hcy, at
pathological concentration, stimulates MCP-1 expression in
human monocytic cell macrophages via NF-kB activation.
Also, in this sense, another study demonstrated that Hcy
might increase monocyte recruitment into developing
atherosclerotic lesions by up-regulating MCP-1 and IL-8
expression in vascular smooth muscle cells(117). In addition,
a study demonstrated that Hcy inhibits TNF-a-induced
activation of the endothelium via the modulation of NF-kB
activity. These results indicate that Hcy alters the response
to injury of endothelial cells, which may have fundamental
impacts on mechanisms of leucocyte recruitment to sites of
inflammation. These findings may indicate a novel pathway
by which Hcy is involved in vascular disorders associated
with homocystinuria(118).
Antioxidant vitamins E and C
Vitamins E and C have been investigated in a large number
of epidemiological, clinical and experimental
studies(119 – 121). Antioxidant nutrients have important roles
in cell function and have been implicated in processes
associated with ageing, including vascular, inflammatory
and neurological damage. The evidence regarding the link
between vitamin E deficiency and neurological sequelae in
man is now firmly established. That several neuropatholo-
gical observations are associated with vitamin E deficiency
indicates the importance of this nutrient in the central
nervous system for normal neurological function(122 – 124).
Vitamin E’s protective effect against cognitive decline and
neurodegenerative disease has been explored in several
epidemiological and clinical studies during the last
decade(125,126). When plasma antioxidants and cognitive
performance in middle-aged and older adults were
measured in the Austrian Stroke Prevention Study, vitamin
E was found to be significantly associated with cognitive
functioning(127). Rosenblum et al.(128) reported a protective
effect by vitamin E to ameliorate the adverse effects of
endothelial cell injury from brain ischaemia.
Recent studies have shown that increased vitamin E
intake slows the progression of dementia and may improve
central nervous system function. A study evaluated the
intake of antioxidants and the risk of stroke, providing
evidence that vitamin E might be of value in reducing the
risk of stroke. This study looked at the diets of over 34 000
postmenopausal women as well as their risk of death from
stroke(24). A total of 215 of the women died of strokes
during the study period. Interestingly, the paper noted that
the greater the amount of vitamin E in the diet, the lower the
risk of death from stroke(24). There was a suggestion of an
inverse association between specific foods rich in vitamin E
and death from stroke. However, these authors found no
reduction in risk of death from stroke with vitamin E
supplements, which might indicate that vitamin E intake
was in fact a surrogate marker for some other protective
agents in the diet.
Prospective studies that examined the association
between vitamin E intake and death from stroke have
produced conflicting results. This is an important area of
research that still remains poorly studied because in most of
the studies there is no detailed information of the dose,
frequency and time that these subjects were taking vitamin
E supplements. However, the Health Professionals Follow-
Up Study looked at nearly 44 000 men aged 40–75 years
without known heart disease or diabetes, and measured the
incidence of stroke, including deaths and all occurrences of
strokes, and compared it with the participants’ intake of
various antioxidants(17). They also found no reduction in the
incidence of stroke in those who took antioxidant
supplements. A study conducted in Helsinki, Finland,
looked at nearly 30 000 male smokers for 6 years(18).
Participants were assigned to take supplements of vitamin
E, b-carotene or placebo. More than 1000 suffered strokes
during the study period. Of those, fewer than 200 had the
type of stroke caused by leaking blood vessels in the brain,
and about 800 had the sort of stroke caused by blockage of
blood vessels from atherosclerosis. The researchers found
that taking vitamin E supplements increased the risk of
strokes from bleeding in the brain among smokers, but
decreased the risk of strokes caused by atherosclerosis in
those participants who had high blood pressure. Strokes
from atherosclerosis also decreased among the diabetics
who took vitamin E supplements, with no associated
increased risk in bleeding strokes(18,129). Thus, the
researchers concluded that vitamin E supplementation
may prevent ischaemic stroke in high-risk hypertensive
patients, but further studies are needed. Results from a study
on vitamin supplements, reported at the 51st annual meeting
of the American Academy of Neurology in Toronto(130),
showed that supplements containing even modest amounts
of vitamin E are protective against ischaemic stroke. This
study shows that vitamin E supplements can reduce
stroke risk by 53 %. The total vitamin E intake of 27 IU/d
(18 mg/d) was significantly lower in subjects who had
sustained an ischaemic stroke than in individuals who had
not had a stroke – their mean total daily intake was 58 IU/d
(38·7 mg/d). Also, controls who had not had a stroke were
also twice as likely to take a vitamin supplement compared
with stroke patients.
Megadoses of vitamin E appear to significantly reduce the
levels of inflammation. Devaraj & Jialal(131) studied forty-
seven men and women with adult-onset, or type 2, diabetes
and twenty-five healthy volunteers. They received 1200 IU
(800 mg) vitamin E daily for 3 months. Before treatment,
individuals with diabetes produced about two-fold as much
C-reactive protein compared with the healthy individuals,
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and individuals with mild diabetes showed about 33 %
higher C-reactive protein levels compared with healthy
volunteers. Interestingly, vitamin E supplementation low-
ered C-reactive protein levels. In addition, these authors also
reported that, after taking vitamin E, cells from the
volunteers produced about 70 % less IL-6 as was generated
by cells from blood drawn before taking vitamin E.
Hodis et al.(132) report results from the Vitamin E
Atherosclerosis Progression Study (VEAPS), a randomised
clinical trial designed to determine the effects of DL-a-
tocopherol supplementation on subclinical atherosclerosis
progression in healthy low-risk individuals. They concluded
that in well-nourished healthy vitamin E-replete individuals
at low risk for CVD, vitamin E supplementation has no
perceptible effect on the progression of atherosclerosis.
Other studies re-examined the preventive role of taking
vitamin E or an inactive placebo for 3 years in men and
women over the age of 40 years(133,134). Those taking
vitamin E had the same amount of plaque build-up on their
arteries as those taking placebo. The authors concluded that
because the study lasted only 3 years, it cannot be ruled out
that vitamin E might confer a protective effect in individuals
taking it for a longer period of time. In addition, the vitamin
E might be beneficial in individuals with kidney disease or
diabetes, who are at increased risk for developing heart
disease.
Another study found that in patients with vascular disease
or diabetes mellitus, long-term vitamin E supplementation
does not prevent cancer or major cardiovascular events and
may increase the risk for heart failure(135). Miller et al.(136)
performed a meta-analysis of the dose–response relation-
ship between vitamin E supplementation and total mortality
by using data from randomised, controlled trials. They
found as limitations that high-dosage (.400 IU/d;
.267 mg/d) trials were often small and were performed in
patients with chronic diseases. Hence, the generalisability of
the findings to healthy adults is uncertain. As conclusion,
they affirm that high-dosage (.400 IU/d; .267 mg/d)
vitamin E supplements may increase all-cause mortality and
should be avoided.
Although some authors have agreed with previous
findings of questionable effects of vitamin E, other studies
show a strong association between dietary vitamin E intake
and risk of stroke, with a distinctive protective role in
diabetes and atherosclerosis. In addition, the long-term
effect of increasing vitamin E intake by using supplements
remains to be determined. In general, studies on vitamin E
and risk of stroke suggest that in women, dietary intake of
vitamin E is protective, but the role of supplements remains
contradictory and while some authors have reported some
benefits, others were unable to confirm these results.
However, vitamin E supplements may be of benefit to
individuals at higher risk of stroke, due to high blood
pressure or diabetes.
Vitamin C is capable of essentially influencing the course
of many metabolic processes, and it is therefore used in the
treatment and prophylaxis of many diseases, including
processes associated with reactive oxygen species and
oxidative stress. Therefore, because it appears that free
radicals are relevant molecules associated with vascular
pathologies, some studies have focused on the possibility of
using vitamin C to lower or eliminate these molecules. In
addition, vitamin C plays significant roles at the molecular
level as a cofactor for several enzymes involved in the
biosynthesis of collagen, carnitine and neurotransmitters. In
fact, some studies have suggested the administration of
vitamin C in the treatment of patients with coronary arterial
disease, treatment of patients after cardiac infarction or cere-
bral stroke, or in the treatment of arterial hypertension(137).
Plasma vitamin C concentration has also been found to be
positively associated with cognitive function(138). Vitamin C
(ascorbic acid) is an extremely effective antioxidant that has
been demonstrated to have potent antioxidant actions in
human plasma and is associated with an 11 % reduction in
stroke prevalence(21,139,140). Vitamin C has been shown to
significantly improve endothelium-dependent vasodilata-
tion in diabetics and patients with coronary artery disease,
perhaps by reducing excess superoxide production, and
thereby decreasing the levels of NO inactivation(141).
Interestingly, there are no studies documenting the role
that vitamin C may have in preventing stroke-mediated
endothelial cell dysfunction. Antioxidant vitamins E and C
may be capable of improving vascular function, quieting
activated glial cells in the brain, and/or reducing the
oxidative-mediated damage, which may be relevant to
ameliorating or preventing the damage caused to neuron
cells by circumscribed inflammatory processes(142 – 144).
Although clinical trials have shown no significant benefit
of vitamin C supplementation in reducing stroke risk, they
were not able to examine the relationship between plasma
vitamin C concentrations and stroke risk in a general
population. Some studies have indicated that vitamin C may
have some role in modulating hypertension, an important
risk of stroke. A study by Kurl et al.(145) examined whether
plasma vitamin C modifies the association between
overweight, hypertension and the risk of stroke in middle-
aged men from eastern Finland. Interestingly, low plasma
vitamin C was associated with an increased risk of stroke,
especially among hypertensive and overweight men. The
recent study by Myint et al. (146) examined the relationship
between baseline plasma vitamin C concentrations and risk
of incident stroke in a British population. The study was
conducted in 20 649 men and women aged 40–79 years
without prevalent stroke at baseline and participating in the
European Prospective Investigation into Cancer-Norfolk
prospective population study. The participants completed a
health questionnaire and attended a clinic between 1993 and
1997, and were followed up for incident strokes through to
March 2005. This study concluded that plasma vitamin C
concentrations may serve as a biological marker of lifestyle
or other factors associated with reduced stroke risk and may
be useful in identifying those at high risk of stroke.
Data regarding the effects of general nutritional status on
stroke risk are limited. There is no evidence that the use of
dietary vitamin E or C supplements or the use of specific
carotenoids substantially reduces the risk of stroke(17). An
analysis of data from the Nurses’ Health Study and the
Health Professionals Follow-Up Study that included
individuals free of CVD at baseline found that the relative
risk of stroke was 0·69 (95 % CI 0·52, 0·92) for individuals
in the highest quintile of fruit and vegetable intake(147).
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An increment of one serving per d was associated with a 6 %
lower risk of stroke. However, it cannot be certain whether
the effect was specifically due to diet or a reflection of a
generally healthier lifestyle in these individuals.
On the other hand, it has been documented that there is a
protective relationship between the consumption of green
leafy vegetables, citrus fruit and juice, and ischaemic
stroke risk(23,147).
Randomised trials have largely failed to support an effect
of antioxidant vitamins on the risk of CVD. Few trials have
examined interactions among antioxidants. The Women’s
Antioxidant Cardiovascular Study tested the effects of
ascorbic acid (500 mg/d), vitamin E (600 IU (400 mg) every
other day) and b-carotene (50 mg every other day) on the
combined outcome of myocardial infarction, stroke,
coronary revascularisation, or CVD death among 8171
female health professionals at increased risk in a 2 £ 2 £ 2
factorial design. Participants were aged 40 years or older
with a history of CVD or three or more CVD risk factors and
were followed up for a mean duration of 9·4 years, from
1995–6 to 2005. There were no significant interactions
between agents for the primary end point, but those
randomised to both active ascorbic acid and vitamin E
experienced fewer strokes(148).
Ullegaddi et al. (149) carried out a randomised controlled
trial to test whether supplementary antioxidants immedi-
ately following acute ischaemic stroke will enhance
antioxidant capacity and mitigate oxidative damage,
concluding that supplementation with antioxidant vitamins
(800 IU (727 mg) a-tocopherol and 500 mg vitamin C for
14 d) within 12 h of onset of acute ischaemic stroke
increased antioxidant capacity, reduced lipid peroxidation
products and may have an anti-inflammatory effect.
Therefore, it is very important to investigate the levels of
vitamins E and C in relation to levels of cytokines, vascular
alterations, and brain changes, and their association with
cognition. The stroke-associated changes in brain vascu-
lature, namely the development of metabolic and functional
changes in the brain associated with impaired cognitive
abilities, is caused by the development of an inflammatory
response following stroke. Products of inflammatory
reactions, such as cytokines, and adhesion molecules,
therefore, may represent extracellular signals that initiate
neuronal degeneration through several intracellular signals.
Micronutrient deficiency will contribute, extending the
cellular events to the cognitive impairment elicited by the
ischaemic insult to the brain.
Oxidative stress
Oxidative stress in stroke patients has been discussed in
many studies, but the results of these studies remain
contradictory(49,150 – 157). Experimental studies have pro-
vided evidence of an association between ischaemic stroke
and increased oxidative stress. In fact, Cherubini et al.(158)
reported a significant reduction in several antioxidants
immediately after an acute ischaemic stroke, possibly as a
consequence of increased oxidative stress. A specific
antioxidant profile is associated with a poor early outcome.
Attention has recently focused on the measurement of
F2-isoprostanes as a sensitive and specific index of
oxidative stress. F2-isoprostanes are a family of eicosanoids
of non-enzymic origin produced by the random oxidation of
tissue phospholipids by oxygen radicals. Several reports
have indicated that isoprostanes are elevated by oxidative
stress. F2-isoprostanes have been proposed as markers of
antioxidant deficiency and oxidative stress, and elevated
levels have been reported in Alzheimer’s disease and heavy
smokers(159,160). Recently, the authors performed a case–
control study of consecutive ischaemic stroke patients
presenting within 8 h of stroke onset. In fifty-two cases and
twenty-seven controls, early (median 6 h post-onset) F2-
isoprostanes were elevated in stroke cases compared with
controls and early plasma F2-isoprostanes correlated with
metalloproteinase-9 in all patients (P ¼ 0·01). The study
concluded that in early human stroke evidence has been
found of increased oxidative stress and a relationship with
metalloproteinase-9 expression, supporting findings from
experimental studies(161). In another study, plasma levels of
F2-isoprostanes were significantly elevated in the stroke
patients compared with the control subjects (P ¼ 0·02)(162).
Interestingly, in the study by Sa´nchez-Moreno et al. (162) an
inverse correlation between plasma vitamin C concentration
and F2-isoprostane levels in the stroke patients, as well as a
positive correlation between C-reactive protein and F2-
isoprostane levels were reported. This finding suggests that
antioxidants may play a very important role in modulating
the levels of inflammatory markers and consequently reduce
the cognitive impairment changes associated with stroke.
Some epidemiological studies have reported on the
effects of lipid peroxidation and antioxidant status on
atherosclerosis and risk for stroke. In a recent study, serum
levels of NO, malondialdehyde and glutathione were
significantly elevated in acute stroke patients(163). Other
groups have evaluated this question by assessing the levels
of thiobarbituric acid-reactive substances and analysed their
relationship with antioxidant status and ultrasonographi-
cally assessed carotid atherosclerosis. A longitudinal study
on cognitive and vascular ageing (Etude sur le Vieillisement
Arteriel; the EVA Study), composed of 1187 men and
women aged 59–71 years without any history of coronary
artery disease or stroke, examined the intima-media
thickness (IMT) on the common carotid arteries (CCA)
and at the site of plaques(164). After adjustment for
conventional cardiovascular risk factors, erythrocyte vita-
min E was significantly and negatively associated with
CCA-IMT in both men and women. Interestingly, although
no association was found between thiobarbituric acid-
reactive substances and CCA-IMT in either sex, thiobarbi-
turic acid-reactive substances were significantly higher in
men with carotid plaques than in those without(164).
Furthermore, this association was strengthened in men
with concentrations of erythrocyte plasma vitamin E below
the lowest quartile.
Conclusions
A large body of evidence suggests that intake of folate and B
vitamins may be beneficial in stroke prevention by reducing
levels of plasma Hcy; however, limited information is
available regarding dietary intake of vitamins or use of
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vitamin supplements by stroke patients. Several studies are
in progress to determine whether treatment with folic acid in
combination with vitamins B6 and B12 will reduce the risk
of stroke in patients with increased serum Hcy. Hcy is
believed to cause atherogenesis and thrombogenesis via
endothelial damage, focal vascular smooth muscle prolifer-
ation probably causing irregular vascular contraction, and
coagulation abnormalities. Therefore, the significance of
any association between CVD and stroke, and circulating
Hcy concentrations is attracting considerable attention.
Antioxidant nutrients have important roles in cell
function and have been implicated in processes associated
with ageing, including vascular, inflammatory and neuro-
logical damage. Prospective studies that examined the
association between vitamin E intake and death from stroke
have produced conflicting results. This is an important area
of research that still remains poorly studied because in most
of the studies there is no detailed information of the dose,
frequency and time that these subjects were taking vitamin
E supplements. In general, studies on vitamin E and risk of
stroke suggest that in women, dietary intake of vitamin E is
protective, but the role of supplements remains contra-
dictory and while some authors have reported some benefits,
others were unable to confirm these results. However,
vitamin E supplements may be of benefit to individuals at
higher risk of stroke, due to high blood pressure or diabetes.
Plasma vitamin C concentration has also been found to be
positively associated with cognitive function. Plasma
vitamin E and C concentrations may serve as a biological
marker of lifestyle or other factors associated with reduced
stroke risk.
As a general conclusion we can affirm that epidemiolo-
gical associations and results of intervention studies suggest
that low B vitamin status, elevated blood Hcy and low
antioxidant status are risk factors for stroke. After reviewing
the observational and intervention studies, there is an
incomplete understanding of mechanisms and some
conflicting findings; therefore the available evidence is
insufficient to recommend the routine use of B vitamins,
vitamin E and vitamin C for the prevention of stroke. A
heart-healthy diet, emphasising fruits and vegetables
containing B vitamins and antioxidants, may be the best
recommendation. Further well-designed controlled clinical
trials are necessary so that the detailed requirements of these
individuals can be better understood.
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